Insider Buying: Surrozen (NASDAQ:SRZN) Major Shareholder Acquires 17,763 Shares of Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Tcg Crossover Gp Ii, Llc purchased 17,763 shares of the company’s stock in a transaction on Wednesday, February 11th. The stock was purchased at an average cost of $23.57 per share, for a total transaction of $418,673.91. Following the purchase, the insider directly owned 650,567 shares in the company, valued at approximately $15,333,864.19. This trade represents a 2.81% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Tcg Crossover Gp Ii, Llc also recently made the following trade(s):

• On Thursday, February 12th, Tcg Crossover Gp Ii, Llc bought 1,093 shares of Surrozen stock. The stock was purchased at an average price of $23.86 per share, for a total transaction of $26,078.98.
• On Tuesday, February 3rd, Tcg Crossover Gp Ii, Llc purchased 4,355 shares of Surrozen stock. The shares were acquired at an average cost of $21.94 per share, with a total value of $95,548.70.
• On Monday, February 2nd, Tcg Crossover Gp Ii, Llc acquired 731 shares of Surrozen stock. The stock was acquired at an average price of $21.38 per share, for a total transaction of $15,628.78.
• On Friday, January 30th, Tcg Crossover Gp Ii, Llc acquired 4,271 shares of Surrozen stock. The stock was acquired at an average cost of $21.39 per share, for a total transaction of $91,356.69.

Surrozen Stock Performance

Surrozen stock traded down $0.36 during mid-day trading on Friday, reaching $24.48. The company’s stock had a trading volume of 53,087 shares, compared to its average volume of 131,820. The company has a market capitalization of $209.82 million, a price-to-earnings ratio of -1.10 and a beta of 0.58. Surrozen, Inc. has a 12 month low of $5.90 and a 12 month high of $25.84. The business’s 50 day simple moving average is $21.51 and its 200 day simple moving average is $15.65.

Analyst Ratings Changes

Several brokerages recently commented on SRZN. Wall Street Zen raised Surrozen to a “sell” rating in a research report on Friday, November 28th. Lifesci Capital upgraded Surrozen to a “strong-buy” rating in a research note on Thursday, November 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Surrozen in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $32.00.

Hedge Funds Weigh In On Surrozen

Several institutional investors and hedge funds have recently modified their holdings of SRZN. Stempoint Capital LP lifted its stake in shares of Surrozen by 185.1% during the 2nd quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock worth $6,138,000 after buying an additional 445,713 shares during the last quarter. Kalehua Capital Management LLC acquired a new position in Surrozen in the 4th quarter valued at about $8,705,000. Stonepine Capital Management LLC lifted its position in Surrozen by 7.1% during the second quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company’s stock worth $2,736,000 after acquiring an additional 20,247 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Surrozen by 21.7% during the third quarter. Vanguard Group Inc. now owns 266,418 shares of the company’s stock worth $3,433,000 after acquiring an additional 47,468 shares during the period. Finally, Acuta Capital Partners LLC grew its position in shares of Surrozen by 5.0% in the third quarter. Acuta Capital Partners LLC now owns 178,415 shares of the company’s stock valued at $2,299,000 after purchasing an additional 8,415 shares during the last quarter. 66.57% of the stock is currently owned by institutional investors and hedge funds.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.